Coherus Oncology, Inc. (CHRS)
Automate Your Wheel Strategy on CHRS
With Tiblio's Option Bot, you can configure your own wheel strategy including CHRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CHRS
- Rev/Share 0.719
- Book/Share 0.7552
- PB 2.336
- Debt/Equity 0.4636
- CurrentRatio 1.2332
- ROIC -1.2282
- MktCap 204482455.0
- FreeCF/Share -0.776
- PFCF -2.2673
- PE 1.3231
- Debt/Assets 0.0788
- DivYield 0
- ROE -5.7472
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CHRS | Maxim Group | Hold | Buy | -- | -- | Sept. 4, 2025 |
| Downgrade | CHRS | UBS | Buy | Neutral | $4 | $1.5 | Aug. 16, 2024 |
News
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations.
Read More
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Published: January 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the high selectivity, picomolar binding affinity and significant effector mediated killing of CCR8+ cells of its investigational anti-CCR8 monoclonal antibody.
Read More
Coherus Oncology: A Two-Pronged March With Mid-2026 Implications
Published: December 23, 2025 by: Seeking Alpha
Sentiment: Positive
Coherus Oncology maintains a 'Buy' rating, driven by a promising clinical pipeline and undervaluation relative to cash and equity holdings. CHRS's commercial growth is anchored by toripalimab sales in a niche U.S. indication, but profitability hinges on pipeline success. Key catalysts include mid-2026 data readouts for casdozokitug and CHS-114; no major Q1 2026 milestones are expected.
Read More
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –
Read More
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer.
Read More
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –
Read More
Coherus Oncology: Five Readouts Or More Possible In 2026
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in hepatocellular carcinoma, CHS-114 in gastric cancer, and CHS-114 in head and neck cancer. There could be further readouts from CHS-114 in 2026 in esophageal squamous cell carcinoma and colorectal cancer.
Read More
About Coherus Oncology, Inc. (CHRS)
- IPO Date 2014-11-06
- Website https://www.coherus.com
- Industry Biotechnology
- CEO Dennis Lanfear
- Employees 228